{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"12"}]}],"title":"Systolic BP (mmHg) , G3 or G4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"}]}],"title":"Diastolic BP (mmHg), G3 or G4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"11"}]}],"title":"Heart rate, Decrease to <60 bpm"},{"categories":[{"measurements":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"28"}]}],"title":"Heart rate, Change to normal or no change"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"18"}]}],"title":"Heart rate, Increase to >100 bpm"}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"54"},{"groupId":"OG002","value":"55"}],"units":"Participants"}],"description":"Blood pressure were summarized according to National Cancer Institutes (NCI) CTCAE grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to G3 or G4 occurred.lood pressure measurement included systolic blood pressure (BP, milimeter of mercury \\[mmHg\\]) and diastolic BP (DBP). Worst case change from Baseline was calculated as the post-Baseline value minus the Baseline value. Heart Rate is the measure of heart beats per minute (bpm). Changes in heart rate, either decrease to \\<60 bpm, change to normal or no change, or increase to \\>100 bpm are presented.","groups":[{"description":"Participants received dabrafenib 150 mg gelatin capsules BID.","id":"OG000","title":"Part C: Dabrafenib 150 mg"},{"description":"Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD.","id":"OG001","title":"Part C: Dabrafenib 150 mg + Trametinib 1 mg"},{"description":"Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD.","id":"OG002","title":"Part C: Dabrafenib 150 mg + Trametinib 2 mg"}],"paramType":"NUMBER","populationDescription":"ATP Population","reportingStatus":"POSTED","timeFrame":"From Baseline (Day 1) until Follow-up visit (up to approximately 7 years)","title":"Part C (Randomized): Number of Participants With the Indicated Worst-case Change From Baseline in Heart Rate and Blood Pressure","type":"PRIMARY","unitOfMeasure":"Participants"}